Lilotomab

Lilotomab is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Nordic Nanovector.

Mechanism of action

Lilotomab works by binding to the CD37 antigen, a protein that is abundantly expressed on the surface of B cells. By binding to this antigen, lilotomab can deliver a dose of radiation directly to the cancer cells, killing them and reducing the size of the tumor.

Clinical trials

Lilotomab has been tested in several clinical trials for the treatment of Non-Hodgkin lymphoma. In these trials, lilotomab was used in combination with Betalutin, a radioimmunotherapeutic agent also developed by Nordic Nanovector.

Side effects

Like all drugs, lilotomab can cause side effects. The most common side effects reported in clinical trials include nausea, fatigue, and anemia. Less common side effects include neutropenia, thrombocytopenia, and lymphopenia.

See also

• Monoclonal antibodies for cancer
• Radioimmunotherapy

References

Lilotomab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski